Context Therapeutics Inc
NASDAQ:CNTX
Context Therapeutics Inc
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-10-20. The firm is engaged in developing small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company’s clinical program for lead candidate, onapristone extended release (ONA-XR), comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Its second program, CLDN6xCD3, is an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing Claudin 6 (CLDN6).
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-10-20. The firm is engaged in developing small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company’s clinical program for lead candidate, onapristone extended release (ONA-XR), comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Its second program, CLDN6xCD3, is an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing Claudin 6 (CLDN6).
